ES2059537T3 - Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina. - Google Patents

Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.

Info

Publication number
ES2059537T3
ES2059537T3 ES88310432T ES88310432T ES2059537T3 ES 2059537 T3 ES2059537 T3 ES 2059537T3 ES 88310432 T ES88310432 T ES 88310432T ES 88310432 T ES88310432 T ES 88310432T ES 2059537 T3 ES2059537 T3 ES 2059537T3
Authority
ES
Spain
Prior art keywords
lymphocine
purging
aid
residual tumor
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88310432T
Other languages
English (en)
Inventor
Joseph H Phillips
Arnon Nagler
Lewis L Lanier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co
Application granted granted Critical
Publication of ES2059537T3 publication Critical patent/ES2059537T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTA UN METODO PARA ELIMINAR CELULAS TUMORALES RESIDUALES DE UN PACIENTE CON UNA ALTERACION NEOPLASICA TRATANDO IN VITRO UNA PREPARACION CELULAR CON CELULAS CITOTOXICAS ACTIVADAS CON LINFOQUINA.
ES88310432T 1987-11-13 1988-11-07 Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina. Expired - Lifetime ES2059537T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/120,299 US5041289A (en) 1987-11-13 1987-11-13 Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells

Publications (1)

Publication Number Publication Date
ES2059537T3 true ES2059537T3 (es) 1994-11-16

Family

ID=22389429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88310432T Expired - Lifetime ES2059537T3 (es) 1987-11-13 1988-11-07 Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.

Country Status (6)

Country Link
US (1) US5041289A (es)
EP (1) EP0317141B1 (es)
JP (1) JPH022345A (es)
AT (1) ATE108659T1 (es)
DE (1) DE3850745T2 (es)
ES (1) ES2059537T3 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69020573T3 (de) * 1989-09-25 1999-12-16 Crc Technology Ltd., London Verfahren zur wachstumshemmung von stammzellen.
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5814295A (en) * 1992-04-10 1998-09-29 The Ohio State University Research Foundation Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy
CA2157379A1 (en) * 1993-03-02 1994-09-15 David S. Terman Method of cancer treatment
US6093381A (en) * 1994-07-13 2000-07-25 Neoprobe Corporation Modulation of the sensitivity of tumor cells to chemotherapeutics
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0002095A3 (en) 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6623923B1 (en) 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
JP2002520054A (ja) * 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
EP1230364A2 (en) * 1999-11-12 2002-08-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2396036A1 (en) * 1999-12-30 2001-07-12 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans

Also Published As

Publication number Publication date
DE3850745T2 (de) 1994-11-24
US5041289A (en) 1991-08-20
DE3850745D1 (de) 1994-08-25
EP0317141B1 (en) 1994-07-20
ATE108659T1 (de) 1994-08-15
JPH022345A (ja) 1990-01-08
EP0317141A3 (en) 1990-04-04
EP0317141A2 (en) 1989-05-24

Similar Documents

Publication Publication Date Title
AU588806B2 (en) Drug, and methods of preparing and using it for treatment of tumors
AU2982889A (en) Novel dosage form of fenofibrate
SE8504720D0 (sv) New drug preparation
ES2010648T3 (es) Formulaciones farmaceuticas de sustancias labiles frente a los acidos para uso oral.
EP0317141A3 (en) Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
FI881876A7 (fi) Menetelmä neurologisten sairauksien hoitoon käytettävän koostumuksen valmistamiseksi.
ES2060399T3 (es) Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento.
ES473709A1 (es) Mejoras en o referentes a un miembro de soporte para una protesis
ES527077A0 (es) Procedimiento para la produccion de una hormona de crecimiento de porcino.
ES542430A0 (es) Un procedimiento para la preparacion de una composicion antiacida de alginato de magnesio.
CA990165A (en) Implant for directed infusion of biologically active substances, a method for its producing and a mold for carrying out said method
SE8701004D0 (sv) Method for therapy of leukemias and certain other malignancies
JPS5090647A (es)
ES8406500A1 (es) Procedimiento para la preparacion de derivados de beta-d-galactosa
JPS5686194A (en) Novel protein and its manufacture
ES2037838T3 (es) Derivados de eritromicina a modificados en c-12.
HUT36783A (en) Process for preparing 1,7-diphenyl-3-methyl-aza-7-cyano-8-methyl-nonane
ES2053623T3 (es) Procedimiento para la preparacion de enzimas fijadas a un soporte.
ES544939A0 (es) Procedimiento para la realizacion de una pieza injertable por via quirurgica dentro de un organismo y pieza obtenida con dicho procedimiento
FR2389625A1 (es)
FR2393565A1 (fr) Procede et dispositif de fixation amovible de protheses, notamment de protheses dentaires
ZA801574B (en) Benzothiazole derivatives,process for their preparation and their therapeutic applications
ES8801624A1 (es) Procedimiento para preparar disulfuros heterociclicos
ES2059479T3 (es) Procedimiento para preparar pregneno-oxazolinas.
IT7924358A0 (it) Antibiotici, procedimento per laloro preparazione, e coltura biologicamente pura per impiego in tale procedimento.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 317141

Country of ref document: ES